Type 2 diabetes mellitus+2
RecruitingStudy of AZD6234 (lenbelintide) Added to Incretin Therapy in Adults with Obesity or Overweight and a Weight‑Related Comorbidity, With or Without Type 2 Diabetes
Study of AZD6234 (lenbelintide) Added to Incretin Therapy in Adults with Obesity or Overweight and a Weight‑Related Comorbidity, With or Without Type 2 Diabetes
- Disease:Type 2 diabetes mellitusObesity+1
- Substances:AZD6234
Denmark- Participants:18–64 years · 65+ years
- Substances:AZD6234
- Sponsor:AstraZeneca AB

